Regulating interface science healthcare products: myths and uncertainties.
Whenever new technology emerges it brings with it concerns and uncertainties about whether or how it will need to be regulated, particularly when it is applied to human healthcare. Drawing on the recent history in the European Union (EU) of the regulation of cell-based medicinal products, and in particular tissue-engineered products, this paper explores the myths that persist around their regulation and speculates on whether the existing regulatory landscape in the EU is flexible enough to incorporate nanotechnology and other new technologies into healthcare products. By untangling these myths a number of clear conclusions are revealed that, when considered in the context of risk-benefit, make it clear that what hinders the uptake of new technology is not regulatory process but basic science.
Bravery
Christopher A
CA
Consulting on Advanced Biologicals Ltd, London, UK. cbravery@advbiols.com
D003695:Delivery of Health Care / Q000331:legislation & jurisprudence; D005062:European Union; D005544:Forecasting; D033161:Government Regulation; D006801:Humans; D036103:Nanotechnology / Q000331:legislation & jurisprudence* / Q000639:trends; D018570:Risk Assessment; D023822:Tissue Engineering / Q000331:legislation & jurisprudence* / Q000639:trends; D035501:Uncertainty